Isofluran Baxter (Isoflurane)

• Isoflurane is used in the anesthetic pathway to provide controlled loss of consciousness for surgical and procedural settings.
• Induction of general anesthesia: rapid onset of unconsciousness for surgical procedures
• Maintenance of general anesthesia: sustained depth of anesthesia throughout operations
• Procedural sedation: provides analgesia and amnesia for short diagnostic or therapeutic procedures

• Isoflurane acts primarily by potentiating the inhibitory neurotransmitter γ‑aminobutyric acid (GABA) at the GABA_A receptor complex, enhancing chloride ion influx and hyperpolarizing neuronal membranes. This depresses neuronal excitability in the central nervous system, leading to reduced synaptic transmission, loss of consciousness, and analgesia. Additional actions include inhibition of excitatory NMDA receptors and modulation of ion channels, contributing to its anesthetic profile.

Isoflurane may be associated with a range of adverse reactions, varying from mild to severe.

Common Side Effects

• Airway irritation: cough or laryngospasm during induction
• Salivation: increased oral secretions
• Nausea: mild postoperative nausea
• Dizziness: transient light‑headedness

Serious or Rare Side Effects

• Malignant hyperthermia: life‑threatening hypermetabolic reaction
• Hepatotoxicity: rare liver enzyme elevation or injury
• Cardiac arrhythmias: severe rhythm disturbances including ventricular tachycardia
• Anaphylaxis: acute allergic reaction with hypotension and airway compromise

• When using Isoflurane, careful patient assessment and monitoring are essential to minimize risks.
• Patient monitoring: continuous cardiovascular and respiratory observation throughout administration
• Airway management: ensure a secured airway and adequate ventilation before inhalation
• Hepatic function: use with caution in patients with pre‑existing liver disease
• Concentration changes: avoid rapid increases in vapor concentration to reduce hypotension risk
• Hypersensitivity: discontinue if signs of allergic reaction such as rash or bronchospasm occur
• Store below 25°C: keep in original sealed container, protect from light and heat

Isoflurane can interact with other medicines, affecting its potency or safety profile.

Major Interactions (Avoid)

• Potent CYP2E1 inhibitors (e.g., disulfiram): may increase isoflurane plasma levels
• Concurrent CNS depressants (e.g., opioids, benzodiazepines): can potentiate respiratory depression
• Malignant hyperthermia‑susceptible agents (e.g., succinylcholine): heighten risk of malignant hyperthermia

Moderate Interactions (Monitor Closely)

• Halogenated anesthetics (e.g., halothane): may enhance hepatic enzyme induction
• Nitrous oxide: can augment cardiovascular effects such as hypotension
• Beta‑blockers: may blunt compensatory tachycardia during anesthesia